Screening Scrutiny

Doctor suggests an extra test and discovers tumor in patient with family history of cancer

Study reports final clinical trial data for advanced kidney cancer treatment

The drug combo pembrolizumab plus axitinib had sustained and durable clinical benefit in more than five years of follow-up. It is a standard-of-care first-line treatment for advanced kidney cancer.

Kimryn Rathmell Named NCI Director

Journal Watch

Study reveals potential new way to stop a common kidney cancer

Vanderbilt researchers have identified cancer cell-specific genetic alterations that reprogram the immune “landscape,” thereby driving tumor growth, and discovered a potential new drug target for stopping it.

Multi-institutional study of Wilms tumor facilitates enrollment, optimizes treatment

Multi-institutional study finds that enrollment and outcomes were similar across various groups of children participating in therapeutic trials for Wilms tumor — the most common pediatric kidney cancer worldwide.